Articles Referencing ARRY
Array Presents ARRY-520 Data - Analyst Blog
4/10/2013, 7:09 pm from Zacks.com in Investing, Business, Stocks
Array BioPharma, Inc. ( ARRY ) recently
presented data on ARRY-520 from two ongoing studies in multiple
myeloma. In 2012, Array BioPharma made progress on its proprietary
programs ARRY-614... Read >>
Gilead Seeks FDA Approval - Analyst Blog
4/9/2013, 5:10 pm from Zacks.com in Investing, Business, Stocks
Gilead Sciences ( GILD ) recently
submitted a New Drug Application (NDA) to the US Food and Drug
Administration (FDA) seeking approval to market its hepatitis C
Virus (HCV) candidate... Read >>
Regeneron Aims HQ Expansion - Analyst Blog
4/8/2013, 6:06 pm from Zacks.com in Investing, Business, Stocks
Regeneron Pharmaceuticals ( REGN ) announced
recently that it intends to expand its corporate headquarters and
laboratories in Westchester County, New York. The move is expected
to create... Read >>
BMY Announces Management Changes - Analyst Blog
4/8/2013, 5:53 pm from Zacks.com in Investing, Business, Stocks
Bristol-Myers Squibb Company ( BMY ) recently
appointed Francis Cuss as its executive vice president and chief
scientific officer. The arrangement is effective from Jul 1, 2013.
Cuss... Read >>
R&D and Iclusig Update from Ariad - Analyst Blog
4/5/2013, 6:08 pm from Zacks.com in Investing, Business, Stocks
Ariad Pharmaceuticals, Inc. ( ARIA ) recently
provided an update on its pipeline and the commercialization of
Iclusig in the US. We remind investors that in Dec 2012, Iclusig gained the US... Read >>
Orphan Status for Insmed's Arikace - Analyst Blog
4/4/2013, 4:07 pm from Zacks.com in Investing, Business, Stocks
The US Food and Drug Administration (FDA) Office of Orphan
Products Development recently granted orphan drug designation to
Insmed Incorporated 's ( INSM ) candidate,
Arikace for the... Read >>
BioMarin Files CTA for BMN-190 - Analyst Blog
4/3/2013, 10:22 am from Zacks.com in Investing, Business, Stocks
BioMarin Pharmaceutical Inc. ( BMRN ) recently
submitted a Clinical Trial Application (CTA) with the Medicines and
Healthcare Products Regulatory Agency (MHRA) in the UK for... Read >>
BMRN Seeks US Approval of Vimizim - Analyst Blog
4/2/2013, 4:17 pm from Zacks.com in Investing, Business, Stocks
BioMarin Pharmaceutical Inc. ( BMRN ) recently
submitted a Biologics License Application (BLA) to the US Food and
Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa).
BioMarin... Read >>
ANTH's Blisibimod Enters Phase III - Analyst Blog
4/1/2013, 7:11 pm from Zacks.com in Investing, Business, Stocks
Anthera Pharmaceuticals Inc. ( ANTH ) recently
initiated the CHABLIS-SC1 phase III study on blisibimod. Blisibimod
is being developed for treating patients suffering from systemic
lupus... Read >>
Pipeline Progress at Pluristem - Analyst Blog
3/25/2013, 6:31 pm from Zacks.com in Investing, Business, Stocks
Israel-based Pluristem Therapeutics Inc. ( PSTI ) recently
reported progress on its phase I/II clinical trial, which is
evaluating the safety and efficacy of its PLacental eXpanded... Read >>
Pipeline Setback at BioLineRx - Analyst Blog
3/25/2013, 4:29 pm from Zacks.com in Investing, Business, Stocks
BioLineRx ( BLRX ) recently
announced disappointing results from an interim analysis of the
phase II/III CLARITY trial of BL-1020. The company's share price
was down by almost 53% on the... Read >>
Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost
3/25/2013, 3:37 pm from Benzinga in Investing, Commodities, Economy, International
Toward the end of trading Monday, the Dow traded down 0.48
percent to 14,452.18 while the NASDAQ dropped 0.33 percent to
3,234.06. The S&P also fell, dropping 0.38 percent to
1,551.26. ... Read >>
Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results
3/25/2013, 1:11 pm from Benzinga in Investing, Commodities, Economy, International
Midway through trading Monday, the Dow traded down 0.41 percent
to 14,453.18 while the NASDAQ dropped 0.37 percent to 3,233.06. The
S&P also fell, dropping 0.30 percent to 1,552.26. ... Read >>
Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit
3/25/2013, 11:03 am from Benzinga in Investing, Commodities, Economy, International
Following the market opening Monday, the Dow traded up 0.31
percent to 14,556.33 while the NASDAQ gained 0.41 percent to
3,258.20. The S&P also rose, gaining 0.47 percent to
1,564.17. ... Read >>
Data on BioMarin's BMN-701 - Analyst Blog
3/21/2013, 6:26 pm from Zacks.com in Investing, Business, Stocks
BioMarin Pharmaceutical Inc. ( BMRN ) recently
announced positive results on BMN-701 from the phase I/II study,
POM-001. BMN-701 is a fusion protein of insulin-like growth factor
2 and acid... Read >>